Organization Overview
Historical Acquisition Tree
Alternative names
Key: Sarepta Therapeutics (4) Acquired (5)
avatrombopag (2018)
casimersen (Amondys 45) (2021 NDA)
delandistrogene moxeparvovec (ELEVIDYS) (2023 NDA)
eteplirsen (Exondys 51) (2016 NDA)
golodirsen (Vyondys 53) (2019 NDA)
LECANEMAB (Leqembi) (2023 NDA)
Key: Sarepta Therapeutics (1) Acquired (39)
adalimumab (humira) (15 trials)
azacitidine (vidaza) (1 trial)
betahistine mesilate (1 trial)
Bunazosin (detantol) (1 trial)
carbamazepine (tegretol) (3 trials)
dalteparin (fragmin) (5 trials)
decitabine (dacogen) (32 trials)
denileukin diftitox (ontak) (14 trials)
eribulin (halaven) (69 trials)
fospropofol (lusedra) (19 trials)
golodirsen (Vyondys 53) (5 trials)
lemborexant (Dayvigo) (28 trials)
lenvatinib (lenvima) (104 trials)
lidocaine (xylocaine) (1 trial)
Menatetrenone (MK-4) (5 trials)
paclitaxel (taxol) (16 trials)
palonosetron (aloxi) (11 trials)
pantoprazole (protonix) (2 trials)
perampanel (fycompa) (61 trials)
Key: Sarepta Therapeutics (3) Acquired (60)
11-valent recombinant human papilloma virus vaccine (1 trial)
adefovir dipivoxil (hepsera) (1 trial)
Belzutifan (Welireg) (3 trials)
bexarotene (targretin) (3 trials)
cabozantinib (cometriq) (1 trial)
capecitabine (xeloda) (7 trials)
carboplatin (paraplatin) (14 trials)
casimersen (Amondys 45) (4 trials)
cisplatin (platinol) (8 trials)
cytarabine (cytosar-u) (4 trials)
diclofenac (voltaren) (2 trials)
docetaxel (taxotere) (7 trials)
doxorubicin (Doxil) (11 trials)
eltrombopag (promacta) (1 trial)
esomeprazole (nexium) (4 trials)
eszopiclone (lunesta) (3 trials)
eteplirsen (Exondys 51) (13 trials)
fluorouracil (efudex) (7 trials)
gemcitabine (gemzar) (7 trials)
lamotrigine (lamictal) (1 trial)
LECANEMAB (Leqembi) (8 trials)
levoleucovorin (fusilev) (1 trial)
oxaliplatin (eloxatin) (5 trials)
pembrolizumab (keytruda) (34 trials)
pemetrexed (alimta) (7 trials)
Key: Sarepta Therapeutics (5) Acquired (67)
4-peptide melanoma vaccine (1 trial)
benznidazole (Rochagan) (1 trial)
bevacizumab (avastin) (6 trials)
bidridistrogene xeboparvovec (2 trials)
calcipotriene (dovonex) (1 trial)
cenobamate (Xcopri) (2 trials)
cetuximab (erbitux) (3 trials)
clofarabine (clolar) (1 trial)
colfosceril palmitate (1 trial)
epirubicin (ellence) (1 trial)
etoposide (vepesid) (3 trials)
Filgrastim (neupogen) (1 trial)
fulvestrant (faslodex) (2 trials)
hyaluronidase (human recombinant) (Hylenex) (1 trial)
idarubicin (idamycin) (1 trial)
interferon alpha-2b (Intron-A) (3 trials)
irinotecan (Camptosar) (6 trials)
ixabepilone (ixempra) (1 trial)
mitoxantrone (novantrone) (1 trial)
ondansetron (zofran) (2 trials)
prednisone (meticorten) (2 trials)
progesterone (progestasert) (1 trial)
raav1.cmv.hufollistatin344 (1 trial)
rasagiline (azilect) (1 trial)
rimabotulinumtoxinB (Myobloc) (2 trials)
sargramostim (leukine) (2 trials)
scaavrh74.tmck.hsgca (1 trial)
sotorasib (LUMAKRAS) (1 trial)
tamoxifen (nolvadex) (1 trial)
tazemetostat (Tazverik) (2 trials)
temozolomide (temodar) (9 trials)
topotecan (hycamtin) (1 trial)
Key: Sarepta Therapeutics (9) Acquired (46)
ethinyl estradiol (Estinyl) (2 trials)
exemestane (aromasin) (1 trial)
fluconazole (diflucan) (2 trials)
flurazepam (dalmane) (1 trial)
incomplete freund's adjuvant (1 trial)
itraconazole (sporanox) (3 trials)
Key: Sarepta Therapeutics (0) Acquired (2)
Cardiovascular Diseases (Phase 2)
Coronary Artery Disease (Phase 2)
Coronary Disease (Phase 2)
Coronary Restenosis (Phase 2)
Encephalitis (Phase 1)
Hemorrhagic Fever, Ebola (Phase 1)
Hemorrhagic Fevers, Viral (Phase 1)
Hepatitis C (Phase 2)
Influenza, Human (Phase 1)
Marburg Virus Disease (Phase 1)
Muscular Dystrophies (Phase 3)
Muscular Dystrophies, Limb-Girdle (Phase 2)
Muscular Dystrophy, Duchenne (Phase 3)
Myocardial Ischemia (Phase 2)
Sarcoglycanopathies (Phase 2)
West Nile Fever (Phase 1)